美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Inspire Corporate Bond ETF

24.01

+0.09000.38%

盤後：24.010.00000.00%16:25 EDT

成交量：6.72萬

成交額：161.35萬

市值：3.87億

市盈率：- -

高：24.06

開：24.00

低：23.92

收：23.92

資料載入中...

總覽公司新聞公告

Organovo Holdings, Inc.股價上漲238.75% 市值漲5209.05萬美元

Organovo Holdings, Inc.盤中異動股價大跌5.15%報0.350美元

Organovo Holdings, Inc.盤中異動股價大跌5.51%

Organovo Holdings, Inc.盤中異動股價大跌5.96%報0.363美元

Organovo Holdings, Inc.盤中異動股價大漲5.82%報0.400美元

Organovo Holdings, Inc.盤中異動早盤快速拉昇5.02%

MNC年報掃描｜巨頭“廝殺” 國產“逐鹿”：自免領域5大單品狂攬近530億美元

21世纪经济报道

【禮來(LLY.US)IL-23p19單抗mirikizumab獲批克羅恩病新適應症】1月15日，禮來(LLY.US)宣佈，其IL-23p19單抗mirikizumab(Omvoh)已獲FDA批准第2項適應症，用於治療成人中度至重度活動性克羅恩病。Mirikizumab繼2023年10月被批准為治療中度至重度活動性成人潰瘍性結腸炎(UC)的同類首創療法之後，現在又被批准用於治療兩種類型的炎症性腸病(IBD)。

MNC年度漲幅榜，意外的榜一

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IBD/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":24.01,"timestamp":1751313600000,"preClose":23.92,"halted":0,"volume":67204,"hourTrading":{"tag":"盘后","latestPrice":24.01,"preClose":24.01,"latestTime":"16:25 EDT","volume":5,"amount":120.35,"timestamp":1751315129013},"delay":0,"floatShares":16100000,"shares":16100000,"eps":0,"marketStatus":"未開盤","change":0.09,"latestTime":"06-30 16:00:00 EDT","open":23.9987,"high":24.0597,"low":23.9199,"amount":1613454.799,"amplitude":0.005844,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1751356800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":23.92,"sharesOutstanding":16100000,"nav":23.88,"aum":384494668.95,"dividendRate":0.042066,"bidAskSpread":0.001911,"postHourTrading":{"tag":"盘后","latestPrice":24.01,"preClose":24.01,"latestTime":"16:25 EDT","volume":5,"amount":120.35,"timestamp":1751315129013},"volumeRatio":1.42356},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":16100000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.42356,"shares":16100000,"dividePrice":1.01,"high":24.0597,"amplitude":0.005844,"preClose":23.92,"low":23.9199,"week52Low":22.84,"pbRate":"--","week52High":25.49,"institutionHeld":0,"latestPrice":24.01,"eps":0,"divideRate":0.042066,"volume":67204,"delay":0,"ttmEps":0,"open":23.9987,"prevYearClose":23.44,"prevWeekClose":23.92,"prevMonthClose":23.74,"prevQuarterClose":23.75,"fiveDayClose":23.93,"twentyDayClose":23.74,"sixtyDayClose":23.79},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514090481","title":"Organovo Holdings, Inc.股價上漲238.75% 市值漲5209.05萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090481","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514090481?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 22:31","pubTimestamp":1740493865,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时31分，Organovo Holdings, Inc.股票出现异动，股价急速上涨238.75%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Organovo Holdings, Inc.、Moleculin Biotech, Inc.、Silexion Therapeutics Corp涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为746.23%、508.78%、459.72%，振幅较大的相关个股有Organovo Holdings, Inc.、Igm Biosciences, Inc.、Bicara Therapeutics Inc.，振幅分别为8.13%、7.46%、5.62%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223105abdc7da6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223105abdc7da6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IBD","ONVO"],"gpt_icon":0},{"id":"2514670511","title":"Organovo Holdings, Inc.盤中異動 股價大跌5.15%報0.350美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514670511","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514670511?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 04:35","pubTimestamp":1740429350,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时35分，Organovo Holdings, Inc.股票出现波动，股价快速跳水5.15%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225043550962ee007&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225043550962ee007&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","IBD","BK4139"],"gpt_icon":0},{"id":"2512480684","title":"Organovo Holdings, Inc.盤中異動 股價大跌5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512480684","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512480684?lang=zh_tw&edition=fundamental","pubTime":"2025-02-20 01:31","pubTimestamp":1739986261,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日01时31分，Organovo Holdings, Inc.股票出现波动，股价快速下跌5.51%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013101988b4e5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013101988b4e5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","ONVO","BK4139"],"gpt_icon":0},{"id":"2512612521","title":"Organovo Holdings, Inc.盤中異動 股價大跌5.96%報0.363美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512612521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512612521?lang=zh_tw&edition=fundamental","pubTime":"2025-02-18 23:25","pubTimestamp":1739892328,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时25分，Organovo Holdings, Inc.股票出现波动，股价大幅下挫5.96%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232528a24ab8fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232528a24ab8fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IBD","ONVO"],"gpt_icon":0},{"id":"2511137666","title":"Organovo Holdings, Inc.盤中異動 股價大漲5.82%報0.400美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511137666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511137666?lang=zh_tw&edition=fundamental","pubTime":"2025-02-15 02:04","pubTimestamp":1739556283,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日02时04分，Organovo Holdings, Inc.股票出现波动，股价大幅上涨5.82%。截至发稿，该股报0.400美元/股，成交量8.5386万股，换手率0.56%，振幅6.08%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.50%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150204439885bb0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150204439885bb0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","IBD","BK4139"],"gpt_icon":0},{"id":"2511243345","title":"Organovo Holdings, Inc.盤中異動 早盤快速拉昇5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511243345","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511243345?lang=zh_tw&edition=fundamental","pubTime":"2025-02-13 23:43","pubTimestamp":1739461383,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时43分，Organovo Holdings, Inc.股票出现波动，股价急速上涨5.02%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.50%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213234303abcdc059&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213234303abcdc059&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","BK4139","IBD"],"gpt_icon":0},{"id":"2509791469","title":"MNC年報掃描｜巨頭“廝殺” 國產“逐鹿”：自免領域5大單品狂攬近530億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509791469","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509791469?lang=zh_tw&edition=fundamental","pubTime":"2025-02-07 16:39","pubTimestamp":1738917574,"startTime":"0","endTime":"0","summary":"随着跨国药企（MNC）陆续披露2024年业绩，21世纪经济报道记者初步统计发现，自免领域的营收排名中，赛诺菲的度普利尤单抗、艾伯维的利生奇珠单抗和阿达木单抗、强生的乌司奴单抗、罗氏的奥瑞利珠单抗位居前5，年内销售额合计529.31亿美元。在这5款产品中，度普利尤单抗作为全球首个获批上市的IL-4Rα靶向单抗，凭借不断拓宽的适应症，成为全球“自免新王”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502073313516026.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502073313516026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CD","IBD","BK4116"],"gpt_icon":0},{"id":"2503916699","title":"【禮來(LLY.US)IL-23p19單抗mirikizumab獲批克羅恩病新適應症】1月15日，禮來(LLY.US)宣佈，其IL-23p19單抗mirikizumab(Omvoh)已獲FDA批准第2項適應症，用於治療成人中度至重度活動性克羅恩病。Mirikizumab繼2023年10月被批准為治療中度至重度活動性成人潰瘍性結腸炎(UC)的同類首創療法之後，現在又被批准用於治療兩種類型的炎症性腸病(IBD)。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503916699","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503916699?lang=zh_tw&edition=fundamental","pubTime":"2025-01-16 21:15","pubTimestamp":1737033339,"startTime":"0","endTime":"0","summary":"1月15日，礼来(LLY.US)宣布，其IL-23p19单抗mirikizumab(Omvoh)已获FDA批准第2项适应症，用于治疗成人中度至重度活动性克罗恩病。Mirikizumab继2023年10月被批准为治疗中度至重度活动性成人溃疡性结肠炎(UC)的同类首创疗法之后，现在又被批准用于治疗两种类型的炎症性肠病(IBD)。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/16211547534225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4516","LU0823416689.USD","IE0002141913.USD","IE00BK4W5L77.USD","LU2237443549.SGD","LU1057294990.SGD","LU1035775433.USD","LU2461242641.AUD","LU2491050071.SGD","LU0058720904.USD","IE0004445239.USD","LU1061106388.HKD","LU2063271972.USD","SGXZ99366536.SGD","LU1868837300.USD","LU2264538146.SGD","LU0094547139.USD","LU0256863811.USD","LU1069344957.HKD","LLY","LU1974910355.USD","LU0385154629.USD","LU0820561818.USD","LU0820561909.HKD","LU1712237335.SGD","LU2023250504.SGD","LU2237443978.SGD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU1988902786.USD","LU1023059063.AUD","LU0672654240.SGD","LU2237443465.HKD","LU0106261372.USD","LU1983299246.USD","IBD","LU2112291526.USD","LU2491049909.HKD","SG9999001176.USD","LU0006306889.USD","GB00BDT5M118.USD","LU0109391861.USD","BK4585","LU0079474960.USD","LU2361045086.USD","SGXZ31699556.SGD","SG9999001176.SGD","LU0320765059.SGD","LU2237438978.USD","LU0203202063.USD"],"gpt_icon":0},{"id":"2502882548","title":"MNC年度漲幅榜，意外的榜一","url":"https://stock-news.laohu8.com/highlight/detail?id=2502882548","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502882548?lang=zh_tw&edition=fundamental","pubTime":"2025-01-10 14:58","pubTimestamp":1736492297,"startTime":"0","endTime":"0","summary":"都说铁打的大药企，流水的biotech。当超9成biotech跌跌不休之际，2022年全球领先的20家药企市值平均增长了5.4%。然而，到了2024年，大药企阵营也发生了分化。而股价涨幅最高的，则是仍处于转型爬坡阶段的梯瓦。整体来看，TOP20中，过去一年股价上涨与下跌企业各占一半。其中，梯瓦、礼来和吉利德是涨幅最高的三家大药企，拜耳、再生元和诺和诺德则是跌幅前三。真正的逆袭者，是以117%涨幅问鼎TOP20榜首的梯瓦。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/248993","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IBD","CD","BK4116"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2025-06-26","symbol":"IBD","amount":0.0953,"announcedDate":"2025-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-26","defaultRemindTime":1750944600000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-26","currency":"USD","dateTimestamp":1750910400000,"payDate":"2025-07-01"},{"date":"2025-05-23","symbol":"IBD","amount":0.0809,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-23","defaultRemindTime":1748007000000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-28","payableDate":"2025-05-23","currency":"USD","dateTimestamp":1747972800000,"payDate":"2025-05-28"},{"date":"2025-04-25","symbol":"IBD","amount":0.0799,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-25","defaultRemindTime":1745587800000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-30","payableDate":"2025-04-25","currency":"USD","dateTimestamp":1745553600000,"payDate":"2025-04-30"},{"date":"2025-03-27","symbol":"IBD","amount":0.092,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-27","defaultRemindTime":1743082200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-27","currency":"USD","dateTimestamp":1743048000000,"payDate":"2025-04-01"},{"date":"2025-02-24","symbol":"IBD","amount":0.0728,"announcedDate":"2025-02-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-24","defaultRemindTime":1740407400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-24","currency":"USD","dateTimestamp":1740373200000,"payDate":"2025-03-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{}}}